The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results
- 作者: Snegovoy A.1, Kononenko I.1, Sorokina I.2, Berezina A.3, Prosianikova O.4
-
隶属关系:
- Lopatkin Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre
- Loginov Moscow Clinical Scientific Center
- Russian Presidential Academy of National Economy and Public Administration
- Biocad
- 期: 卷 25, 编号 3 (2023)
- 页面: 378-384
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/148906
- DOI: https://doi.org/10.26442/18151434.2023.3.202452
- ID: 148906
如何引用文章
全文:
详细
Aim. To assess the proportion and profile of patients at high risk of febrile neutropenia (FN) receiving cytotoxic chemotherapy (CT), as well as the incidence of FN and dose-limiting neutropenia after one cycle of CT.
Materials and methods. The paper presents the results of the FLAME study, the first Russian observational study in patients with solid tumors who received only cytotoxic CT or a combination with targeted, immuno-oncological drugs. By random sampling, the study retrospectively included 500 patients with a median age of 59 years (18–83 years) from 25 medical institutions in the Russian Federation.
Results. CT regimens with a high (>20%) risk of FN were received by 25.2% (126/500) of patients; 53% (265/500) of patients had intermediate risk, and half of them (132/265 [49.8%]) had at least one additional risk FN factor following international NCCN guidelines. Thus, a high risk of FN, according to the therapy and the assessment of individual prognostic adverse factors, was noted in 51.6% (258/500) of patients. 36.8% (95/258) of patients with high risk for FN received primary prophylaxis with granulocyte colony-stimulating factors.
Conclusion. The study showed a significant proportion of patients with a high risk of FN, and most of them do not receive primary prophylaxis of FN.
作者简介
Anton Snegovoy
Lopatkin Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre
编辑信件的主要联系方式.
Email: drsneg@gmail.com
ORCID iD: 0000-0002-0170-5681
d. sci. (med.), prof.
俄罗斯联邦, MoscowInessa Kononenko
Lopatkin Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre
Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-7142-2986
cand. sci. (med.)
俄罗斯联邦, MosocwIrina Sorokina
Loginov Moscow Clinical Scientific Center
Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-9404-3698
cand. sci. (biol.)
俄罗斯联邦, MoscowAnna Berezina
Russian Presidential Academy of National Economy and Public Administration
Email: editor@omnidoctor.ru
ORCID iD: 0009-0007-9140-8747
independent expert of research projects
俄罗斯联邦, MoscowOxana Prosianikova
Biocad
Email: editor@omnidoctor.ru
ORCID iD: 0009-0005-3684-6301
cand. sci. (med.)
俄罗斯联邦, Saint Petersburg参考
- Кононенко И.Б., Снеговой А.В., Ларионова В.Б. Нейтропения, лимитирующая проведение химиотерапии. Нужна ли профилактика? Онкогематология. 2022;17(1):135-42 [Kononenko IB, Snegovoy AV, Larionova VB. Chemotherapy limiting neutropenia. Is prevention required? Oncohematology. 2022;17(1):135-42 (in Russian)]. doi: 10.17650/1818-8346-2022-17-1-135-142
- Fortner BV, Houts AC, Johnson G, Schwartzberg LS. A prospective investigation of chemotherapy induced neutropenia (CIN) and quality of life (QoL). J Clin Oncol. 2005;23(16):suppl.8178.
- Wang CY, Heldermon CD, Vouri SM, et al. Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance, From 2014 to 2019. JAMA Network Open. 2021;4(11):e2133474.
- Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199-212.
- Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(Suppl. 5):v111–8.
- Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8-32.
- Снеговой А.В., Кононенко И.Б., и др. Протоколы клинических рекомендаций поддерживающей терапии в онкологии. Под ред. акад. РАН М.И. Давыдова. Протокол профилактики фебрильной нейтропении гранулоцитарными колониестимулирующими факторами. 2023-2024; с. 24-35 [Snegovoi AV, Kononenko IB, et al. Protokoly klinicheskikh rekomendatsii podderzhivaiushchei terapii v onkologii. Pod red. akad. RAN MI Davydova. Protokol profilaktiki febril'noi neitropenii granulotsitarnymi koloniestimuliruiushchimi faktorami. 2023-2024; p. 24-35 (in Russian)].
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloid Growth Factors. V2.2023.NCCN
- Wang Y, Chen L, Liu F, et al. Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network metaanalysis. Sci Rep. 2019;9:15374. doi: 10.1038/s41598-019-51982-4
- Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical PracticeGuideline Update. J Clin Oncol. 2015;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488
- Клинические рекомендации МЗ РФ «Опухоли невыявленной первичной локализации». 2021. ID:504. Режим доступа: https://cr.minzdrav.gov.ru/recomend/504_2. Ссылка активна на 15.06.2023 [Clinical recommendations of the Ministry of Health of the Russian Federation “Tumors of unidentified primary localization.” 2021. ID:504. Available at: https://cr.minzdrav.gov.ru/recomend/504_2. Accessed: 15.06.2023 (in Russian)].
- Клинические рекомендации МЗ РФ «Рак молочной железы». 2021. ID:379. Режим доступа: https://cr.minzdrav.gov.ru/recomend/379_4. Ссылка активна на 15.06.2023 [Clinical recommendations of the Ministry of Health of the Russian Federation “Breast cancer”. 2021. ID:379. Available at: https://cr.minzdrav.gov.ru/recomend/379_4. Accessed: 15.06.2023 (in Russian)].
- Сапожников К.В., Сорокина И.В., Гусев А.В., и др. Профилактика фебрильной нейтропении у онкологических пациентов: данные реальной клинической практики. Современная Онкология. 2023;25(1):115-22 [Sapozhnikov KV, Sorokina IV, Gusev AV, et al. Prevention of febrile neutropenia in oncological patients: real-world data. Journal of Modern Oncology. 2023;25(1):115-22 (in Russian)]. doi: 10.26442/18151434.2023.1.202138
- Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18(13):2522-8. doi: 10.1200/JCO.2000.18.13.2522
- Криворотько П.В., Бурдаева О.Н., Ничаева М.Н., и др. Эффективность и безопасность препарата Экстимия® (эмпэгфилграстим) у пациентов с диагнозом «рак молочной железы», получающих миелосупрессивную химиотерапию: результаты двойного слепого сравнительного клинического исследования III фазы. Современная Онкология. 2015;17(2):45-52 [Krivorotko PV, Burdaeva ON, Nechaeva MN, et al. Efficacy and safety of Extimia® (empegfilgrastim): results of a doubleblind controlled phase III study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy. Journal of Modern Oncology. 2015;17(2):45-52 (in Russian)].
- Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017;25:3295-3304. doi: 10.1007/s00520-017-3842-1
- Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40(3):402-7. doi: 10.1345/aph.1G516
- Family L, Li Y, Chen L, et al. A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora, J Natl Compr Canc Netw. 2018;16(10):1201-8. doi: 10.6004/jnccn.2018.7051
- Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117:1917-27. doi: 10.1002/cncr.25691
- Goodin C, Ratliff P, Cottingham L, Shely R, et al. Assessing febrile neutropenia outcomes in patients receiving primary versus secondary prophylactic G-CSF treatment therapy with intermediate neutropenic risk chemotherapy regimens. J Oncol Pharmacy Practice. 2022;28(7). doi: 10.1177/10781552211035739
- Campbell K, Chadha N, Dimri S, et al. G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. Exp Rev Hematol. 2022;15(7):619-33. doi: 10.1080/17474086.2022.2093712
- Ашоур А.З., Литовкин А.В., Белов В.Г., и др. Анализ медико-социальных потребностей онкологических пациентов старшей возрастной группы при оказании паллиативной помощи. Современные проблемы науки и образования. 2015;5:335 [Ashour АZ, Litovkin VA, Belov VG, et al. Analysis of health and social needs of cancer patients of older age groups in palliative care. Sovremennyie problem nauki I obrazovaniia. 2015;5:335 (in Russian)].
- Литовкин А.В., Парфенов Ю.А., Парфенов С.А., Сапожников К.В. Формы оказания паллиативной помощи лицам старшей возрастной группы с онкологией. Современные проблемы науки и образования. 2017;4:58 [Litovkin AV, Parfenov IuA, Parfenov SA, Sapozhnikov KV. Formy okazaniia palliativnoi pomoshchi litsam starshei vozrastnoi gruppy s onkologiiei. Sovremennyie problem nauki I obrazovaniia. 2017;4:58 (in Russian)].
- Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022 [Zlokachestvennyie novoobrazovaniia v Rossii v 2021 godu (zabolevaiemost' i smertnost'). Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. PA Gertsena − filial FGBU «NMITS radiologii» Minzdrava Rossii, 2022 (in Russian)].
- WHO Global Cancer Facts & Figures. American Cancer Society. 4th Edition, 2018.